Mersana Therapeutics
CAMBRIDGE, MA · CIK 0001442836 · Biotech · Acquired
antibody-drug conjugates (ADCs) for cancer treatment
mersana.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $69M
- 6 Form D · Jun 2016
- 123 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 40
- 20 granted · 20 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20092010201120122013201420152016
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $2,500,000 | |
| Private capital raised | Form D · SEC | $6,000,000 | |
| Private capital raised | Form D · SEC | $12,500,164 | |
| Private capital raised | Form D · SEC | $4,999,994 | |
| Private capital raised | Form D · SEC | $10,128,576 | |
| Private capital raised | Form D · SEC | $33,099,988 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 1965 | GLYCYX MOR, INC. | — | — |
| 1966 | ARMR Sciences Inc. | — | $30M |
| 1967 | AOBiome LLC | — | $3.7M |
| 1968 | Mersana Therapeutics | — | $69M |
| 1969 | F-STOP, LLC | — | $85K |
| 1970 | CMP TARNHELM PARTNERS, LLC | — | — |
| 1971 | VAST THERAPEUTICS, INC. | — | — |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Nicholas BacopoulosDirector · Executive Officer
- Nicholas BacopoulousDirector
- Thomas BeckDirector
- THOMAS BECKDirector
- Donald BergstromExecutive Officer
- DONALD BERGSTROMExecutive Officer
- Burkhard BlankExecutive Officer
- C. BoydDirector
- C. ClarkeDirector
- Wayne FosterExecutive Officer
- WAYNE FOSTERExecutive Officer
- Karen HongDirector
- Eva JackExecutive Officer
- EVA JACKExecutive Officer
- ELAINE JONESDirector
- MICHAEL KAUFMANExecutive Officer
- Peter LeoneExecutive Officer
- Timothy LowingerExecutive Officer
- TIMOTHY LOWINGERExecutive Officer
- Michael MetzgerExecutive Officer
- David MottDirector · Executive Officer
- DAVID MOTTDirector · Executive Officer
- Sara NayeemDirector
- SARA NAYEEMDirector
- Julie OlsonDirector · Executive Officer
- Peter ParkExecutive Officer
- PETER PARKExecutive Officer
- ANNA PROTOPAPASDirector · Executive Officer
- Joyce TsangDirector
- Martin VogelbaumDirector
Patents
- Antibody Drug Conjugates Comprising Sting Agonistsapplication
- Antibody Drug Conjugates Comprising Sting Agonistsgranted
- Monoclonal Antibodies Against HER2 Epitope And Methods Of Use Thereofapplication
- Sting Agonist Compounds And Methods Of Useapplication
- Antibody Drug Conjugates Comprising Sting Agonistsgranted
- Peptide-containing Linkers For Antibody-drug Conjugatesapplication
- B7H4-TARGETED Antibody-drug Conjugates And Methods Of Use Thereofapplication
- Site Specific Antibody-drug Conjugates With Peptide-containing Linkersapplication
- Peptide-containing Linkers For Antibody-drug Conjugatesgranted
- B7H4-TARGETED Antibody-drug Conjugates And Methods Of Use Thereofgranted
- Sting Agonist Compounds And Methods Of Usegranted
- B7-H4-TARGETED Antibody-drug Conjugates For The Treatment Of Cancerapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.